1446350-60-2
基本信息
物理化學(xué)性質(zhì)
常見問題列表
Proteasome assembly
TCH-165 (0.01-10 μM; 72 hours; RPMI8226 and U87MG cells) treatment inhibits cell growth of RPMI8226 and U87MG cells with IC50 of 1.6 μM and 2.4 μM, respectively.
TCH-165 (0-10 μM; 24 hours; HEK293T cells) treatment enhances ODC degradation is blocked by BTZ indicated that this event is proteasome-mediated. TCH-165 enhances proteolytic degradation in a concentration-dependent manner.
TCH-165 enhances the chymotrypsin-like (CT-L), trypsin-like (Tryp-L) and caspase-like (Casp-L) activities with EC
50
s of 4.2 μM, 3.2 μM and 4.7 μM, respectively.
TCH-165 enhances 20S-mediated degradation of IDPs, α-syn, and tau in vitro, and does not induce the degradation of structured proteins such as GAPDH.
TCH-165-treated cells display a decrease in the assembled 26S and an increase in the 20S proteasome. TCH-165 regulates the dynamic equilibrium between the 20S and 26S proteasome complexes, favoring 20S-mediated protein degradation.
Cell Viability Assay
Cell Line: | RPMI8226 and U87MG cells |
Concentration: | 0.01-10 μM |
Incubation Time: | 72 hours |
Result: | Inhibited cell growth of RPMI8226 and U87MG cells with IC 50 of 1.6 μM and 2.4 μM, respectively. |
Western Blot Analysis
Cell Line: | HEK293T cells |
Concentration: | 0 μM, 3 μM, 10 μM |
Incubation Time: | 24 hours |
Result: | Enhanced proteolytic degradation in a concentration-dependent manner. |